Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification factor to be incorporated into the underlying basal profile which was running at the time the periodic monitoring of the analyte levels were performed.

A vapor delivery system is provided that may include any of a number of features. One feature of the vapor delivery system is that it can apply condensable vapor energy to tissue, such as a prostrate, to shrink, damage, or denature the prostate. In some embodiments, the vapor delivery system can include safety features including prostate capsule detection, needle tracking, and treatment tracking. Methods for safe and effective treatment of prostate tissues are presented.

An apparatus including a controller can determine a rate of change of a blood glucose level of a subject from blood glucose data and determine if there is a risk of the blood glucose level going high or low.

The present disclosure relates to a liquid medicine injection device including a patch portion to which a sensor portion configured to measure blood glucose is detachable and in which an injection portion configured to inject a liquid medicine into the body of a user is installed, and a stamping portion on which the patch portion is mounted and including a first needle connectable to the sensor portion, wherein the stamping portion transmits power to the patch portion so that the first needle and a second needle, which is connected to the injection portion, are together inserted into the skin of the user, and the sensor portion and the injection portion are installed in a single device so that the convenience of use is improved when the liquid medicine injection device is attached to the skin of the user.

A system and method is provided for monitoring a biological substance in a bodily orifice. The system includes a wearable device configured to be worn in a bodily orifice. A biosensor is carried by the wearable device and is constructed and arranged to obtain raw data regarding a biological substance in the orifice. The biosensor includes a processor circuit to provide processed data from the raw data, and a transmitter to wirelessly transmit the processed data to a second device.

In some examples, a system includes a glucose sensor configured to generate a signal indicative of a blood glucose level of a patient, a medical device configured to deliver insulin to the patient, a peritoneal dialysis (PD) device, and control circuitry. The control circuitry is configured to control the PD device to deliver PD therapy to a patient during a PD cycle, determine a blood glucose level of the patient during the PD cycle based on a signal from the glucose sensor, determine that the blood glucose level is greater than or equal to a predetermined blood glucose level threshold, and control the medical device to deliver insulin to the patient in response to determining the blood glucose level is greater than or equal to the predetermined blood glucose level threshold.

The present disclosure provides a pharmaceutical composition for multi-stage release of psychoactive substances including cannabinoids. The pharmaceutical composition comprises two or more staged compositions having different release profiles or different release time such that the one or more active agents in each of the two or more staged compositions are released into the subject's blood stream at different time points.

Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device involves obtaining one or more measurement values of a physiological condition in the body of a user during an initial monitoring period and determining a fasting reference value for a metric based on the one or more measurement values. After the initial monitoring period, the method continues by obtaining an updated measurement value during a fasting period, determining a current value for the metric based at least in part on the updated measurement value, and generating a notification in response to a deviation between the current value and the fasting reference value exceeding a threshold indicative of insertion site loss or other loss of effectiveness.

Blood glucose control systems are disclosed. A blood glucose control system can receive a glucose level signal from a glucose sensor operatively coupled to a subject. The system can decode encoded data of the glucose level signal to obtain the glucose level of the subject and the indication of the glucose trend. The system can automatically calculate the dose control signal using a control algorithm configured to calculate regular correction boluses of glucose control agent in response to at least the glucose level of the subject. The system can select a dose control signal encoding profile from a plurality of dose control signal encoding profiles and, based on the dose control signal encoding profile, encode the dose control signal such that the pump controller can read the dose control signal. The system can transmit an encoded dose control signal to the pump controller.

A system including a sensor interface coupled to a processor. The sensor interface is configured to receive and process an analog electrocardiogram signal of a subject and provide a digitized electrocardiogram signal sampled over a first time period and a second time period that is subsequent to the first time period. The processor is configured to receive the digitized electrocardiogram signal, to analyze a frequency domain transform of the digitized electrocardiogram signal sampled over the first and second time periods and determine first and second metrics indicative of metabolic state of a myocardium of the subject during the first and second time periods, respectively, to compare the first and second metrics to determine whether the metabolic state of the myocardium of the subject is improving, and to indicate administration of an intervention to the subject in response to a determination that the metabolic state is not improving.